抑制循环氧化原酶-2会导致心力衰竭,并保留喷射分数
bioRxiv : the preprint server for biology
|December 9, 2024
概括
循环氧化酶-2 (COX-2) 抑制会损害心脏透静功能,导致雌性小鼠,斑马鱼和人类的心脏衰竭. 这种效应与处理不平衡有关.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 分子医学是分子医学.
背景情况:
- 非类固醇抗炎药物 (NSAIDs),特别是循环氧化酶-2 (COX-2) 抑制剂,与不良心血管事件有关,包括心力衰竭.
- 对COX-2抑制对不同类型心力衰竭 (心力衰竭减少或心力衰竭保持) 的具体影响尚不清楚.
研究的目的:
- 调查COX-2抑制是否优先导致心力衰竭与保留喷射率 (HFpEF) 或心力衰竭与减少喷射率 (HFrEF).
- 阐明COX-2抑制诱导的心脏功能障碍的潜在机制.
主要方法:
- 使用了老年雌性诱导性COX-2淘汰 (iCOX-2 KO) 鼠和幼虫斑马鱼模型.
- 向斑马鱼幼虫施用了赛莱科克西布 (一种COX-2抑制剂).
- 分析心脏功能,包括射出分数 (EF) 和透静功能.
- 检查的血N-终端亲B型尿素 (BNP) 水平.
- 在心脏组织中研究基因表达,蛋白质水平 (胺,SERCA2a) 和处理.
- 追溯分析了暴露于COX-2选择性NSAIDs的糖尿病患者的电子病历.
主要成果:
- 年龄较大的雌性iCOX-2 KO小鼠表现出腹功能障碍,心脏缩和BNP升高,EF保持不变,与雄性不同.
- 斑马鱼的COX-2抑制导致心率降低和腹功能障碍,EF保持和BNP增加.
- 对人类患者数据的分析显示,与HFrEF相比,COX-2选择性NSAID使用和HFpEF风险之间存在更强的联系.
- 在雌性iCOX-2 KO小鼠中,心肌放松受损与处理的改变有关,特别是斯兰本与SERCA2a比率的增加.
结论:
- 抑制COX-2并不会损害心脏缩功能,但会诱导心力衰竭,具有保留喷射分数 (HFpEF) 现型.
- 在COX-2抑制后在小鼠,斑马鱼和人类中观察到的HFpEF表型是由由于处理不平衡而导致心肌放松受损的介导.
- 这些发现强调了一种特定的机制,通过该机制,COX-2抑制剂可以促进HFpEF.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:22Heart Failure Drugs: Diuretics
340
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
517
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
517